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doi:10.1016/j.ejvs.2010.01.015Abstract Objectives: Restenosis following remote superficial femoral artery endarterectomy
(RSFAE) remains a challenging problem. The determinants predicting failure are lacking. This
study investigated patient characteristics with predictive value for restenosis during the first
year after RSFAE.
Design: A prospective cohort study.
Materials and methods: A total of 90 patients post-RSFAE were studied for the occurrence of
restenosis (peak systolic velocity ratio 2.5) in the first 12 months postoperatively. At baseline,
clinical parameters were recorded. Vessel size wasmeasured on the basis of plaque perimeter in
the culprit lesion and lumen diameter on perioperative digital subtraction angiography.
Results: In 57 patients (63%), a restenotic lesion was diagnosed within 12 months following
surgery. Patients with longer time interval between start of ischaemic walking complaints and
RSFAE revealed a significantly higher incidence of restenosis (hazard ratio (HR) Z 1.3 (1.05e
1.52) per 4 years). Small plaque perimeter and small superficial femoral artery (SFA) diameter
on angiography were significantly associated with restenosis (HR Z 0.54 (0.34e0.88) per
10mmand HRZ 0.46 (0.27e0.78) per 1.5mm, respectively). Inmultivariate analysis, age, dura-
tion of ischaemic walking complaints and lumen diameter were independently associated with
increased risk of restenosis after RSFAE.
Conclusions: This study provides evidence that age, vessel size and duration of ischaemic
walking complaints before RSFAE are predictive values for restenosis after RSFAE.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.rkamp, MD, PhD, Experimental Cardiology Laboratory, University Medical Center Utrecht, G02.523,
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598 W.J.M. Derksen et al.Remote superficial femoral artery endarterectomy (RSFAE)
is established as a minimally invasive treatment option for
long occlusions, defined as TransAtlantic Inter-Society
Consensus (TASC)1 C and D lesions of the superficial
femoral artery (SFA). RSFAE has comparable primary-
assisted and secondary patency rates to prosthetic supra-
genicular bypass surgery.2 Besides, hospital stay is shorter
and consequences of possible re-obstructions are less
severe in patients treated with RSFAE.2,3
A drawback of RSFAE is the restenosis rate in the first
year postoperatively caused by neo-intimal hyperplasia,
with more than 80% of all restenoses occurring in the first
year after surgery. Restenosis within the first year has been
associated with a higher risk for occlusion. The restenotic
lesions are equally distributed in the endarterectomised
SFA, including the distal part of the SFA with the stented
transection zone.4
The determinants predicting failure after RSFAE are
lacking. The general risk factors for cardiovascular disease
are not successful in discriminating the risk for restenosis.
The extent and severity of the treated lesion and technical
considerations are determinants of failure after percuta-
neous interventions or bypass surgery.5 However, these
clinical characteristics have not yet been proven to be of
value for predicting restenosis after RSFAE. The objective
of this study was to investigate patient characteristics that
have a predictive value for restenosis during the first year
after RSFAE.
Materials and Methods
Study population
All patients in the current study were included in the
Athero-Express Biobank, an ongoing vascular biobank with
a longitudinal study design that has been described previ-
ously.6 Dissected femoral plaques, obtained by endarter-
ectomy in two participating Dutch teaching hospitals, were
collected and examined histopathologically. In addition,
clinical baseline characteristics of all included patients
were obtained. The medical ethics boards of both partici-
pating hospitals approved the study, and all patients
provided written informed consent.6
In both hospitals, patients suffering from SFA obstruc-
tions were treated by use of the same protocol. Patients
without improvement or worsening of their complaints
after supervised exercise, and patients with critical
ischaemia primarily, were discussed in a multidisciplinary
meeting. If the patients did have a suitable greater
saphenous vein (>3 mm), TASC C lesions, assessed as too
complicated for percutaneous intervention, and TASC D
lesions were treated with a venous supragenicular bypass.
If the patients with extensive TASC C and TASC D SFA lesions
did lack a suitable greater saphenous vein, they were
treated primarily with RSFAE. Only when RSFAE failed that
patients received a prosthetic supragenicular bypass.
A total of 90 consecutive patients who underwent RSFAE
between February 2003 and October 2007 were selected.
All patients underwent unilateral RSFAE with or without an
additional open endarterectomy of the common femoral
artery. All patients presented with intermittentclaudication, critical ischaemia or tissue loss (Rutherford
category 3e5)7 due to long-segment occlusion (TASC C and
D lesions) of the SFA.
At baseline, clinical preoperative, perioperative and
postoperative parameters were obtained from the Athero-
Express medical database. Missing data were obtained from
medical files or referral letters. The preoperative evalua-
tion included a magnetic resonance angiography (MRA).
RSFAE technique
This minimally invasive debulking technique has been
described previously.8 In summary, the SFA is exposed
through a small groin incision. After anticoagulation with
heparin, the proximal SFA is clamped, and a longitudinal
arteriotomy is made in the proximal SFA. The intima core is
dissected, between the lamina elastica interna and the
circular fibres of the media, using the Vollmar dissector
(Vollmar Dissector, Aesculap, San Francisco, CA, USA),
until it reaches the distal limit of the atheroma in the SFA.
The Vollmar dissector is then exchanged for the Mollring
Cutter (LeMaıˆtre Vascutek, San Jose, CA, USA). This
device can transect and remove the entire desobstructed
intimal core, all under fluoroscopic guidance. After the SFA
is debulked, the distal transaction zone is secured by
a stent and a completion angiography is performed to check
the patency of the SFA and outflow arteries.
Atherosclerotic plaque
The excised plaques were directly transferred to the
laboratory, processed and examined as described previ-
ously.6 The atherosclerotic lesions were dissected into 5-
mm segments, and the segment with the greatest plaque
area was defined as the disease-causing lesion. This
segment was fixed in formaldehyde 4%, decalcified for 1
week in ethylenediaminetetraacetic acid and embedded in
paraffin. The segments adjacent to the causative lesion
were snap-frozen in liquid nitrogen and stored at 80 C for
future analysis.6
Arterial size
Cross sections of the elastin von Gieson staining of the
harvested atherosclerotic plaques were captured by digital
image microscopy (AnalySiS version 3.2, Soft Imaging
GmbH, Munster, Germany), and the perimeter of the pla-
que was measured in each cross section by tracing the
internal elastic lamina (Fig. 1). As the studied femoral
atherosclerotic plaques are dissected between the internal
elastic lamina and the circular fibres of the media, we
assumed that the perimeter of the dissected atheroscle-
rotic plaque (the perimeter of the internal elastic lamina) is
a measure of preoperative artery size.
The diameter of the arterial lumen was also measured
on angiography performed at the end of the procedure as
a measure for residual lumen size. All angiographies were
stored in an electronic database, and all patients received
an aSpire stent (LeMaitre Vascular, San Jose, CA, USA) to
secure the transaction zone in the distal SFA. The distance
between two nitinol frames of the double-helix
Figure 1 Measurement of the perimeter of the plaque in the culprit lesion of the occluded superficial femoral artery. A: Elastin
van Gieson staining of the atherosclerotic plaque. Inlay: magnification of the marked area showing the internal elastic lamina in
black (arrow). BarZ 1 mm. B: Measurement of the perimeter of plaque by tracing the internal elastic lamina (in red) using digital
image microscopy.
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This distance between the two nitinol frames at four
helices of one aSpire stent was measured and averaged
and used for calibration. Next, the SFA lumen diameter was
measured at three standardised levels: 1, 3 and 5 cm
proximal of the stent in the distal SFA. The measurement
outcomes at the three fixed points were then averaged. An
interventional radiologist supervised the execution of all
angiographic measurements and measurements were per-
formed with the computer systems of our radiologists
(Picture Archiving and Communications System (PACS) from
Agfa-Gevaert Group).
Follow-up
Restenosis after initially successful RSFAE most often occurs
in the first year postoperatively. These restenotic lesions
have to be treated at an early stage to maintain patency
whether symptomatic or not.9 Follow-up, including history,
physical examination and duplex ultrasound scanning, was
scheduled at 3, 6 and 12 months and annually thereafter.
Duplex ultrasound scanning to detect restenotic lesions was
performed according to protocol. The entire common
femoral artery, the proximal profunda femoral artery, the
entire SFA (from origin till popliteal artery, including distal
stent) and the entire popliteal artery were scanned in every
patient. Obstructions are classified on the base of the peak
systolic velocity (PSV) within the obstruction (numerator of
the PSV ratio) and distally of the obstruction (denominator
of the PSV ratio). If the stenotic lesion is at the distal end of
the artery, the PSV of the denominator will be measured
proximal to the lesion. A stenosis of 50% is considered if the
PSV ratio is 2.5. We considered a restenotic lesion if there
was a lumen reduction of 50% or more (ZPSV ratio  2.5).
Additional MRA may be performed in case of restenosis at
the preference of the treating vascular surgeon.
Data analysis
Statistical analysis was performed with SPSS version 15.0
software (SPSS Inc, Chicago, IL, USA). In univariate analysis,
the association between baseline data and restenosis wastested for significance with the Cox regression analysis.
Hazard ratios (HRs) were calculated. The 95% confidence
intervals (CIs) not containing 1 or values of P < 0.05 were
considered statistically significant. To test independency of
the univariate variables, multivariate Cox regression anal-
ysis (with backward exclusion of non-significant variables
using likelihood ratio test) was performed. Variables
showing an association with restenosis (P < 0.1) in univar-
iate analysis were included in the multivariate analysis.
Furthermore, age, sex and operation indication were
always included in the multivariate analysis models.
Results
The study included 90 consecutive patients (74% men)
undergoing unilateral RSFAE between February 2003 and
October 2007. The baseline patient characteristics are
summarised in Table 1. Mean patient age was 67 years. In 72
patients (80%), Rutherford category 3 was the indication for
operation. The median duration of ischaemic walking
complaints due to SFA occlusion before surgery was 56
months (range: 4e303 months).
A restenotic lesion was diagnosed in 57 patients (63%)
within 12 months after RSFAE, including one patient with an
early restenosis (<30 days). Of the 57 patients with reste-
nosis, 47 (82%) were symptomatic. Thirty-four patients (72%)
had claudication complaints (Rutherford category 2 or 3);
eight (17%) presentedwith critical leg ischaemia (Rutherford
category 4) and three (6%) had tissue loss (Rutherford cate-
gory 5). In addition, two patients (4%) were re-admitted with
acute critical leg ischaemia.
Twenty patients were asymptomatic or had Rutherford
class 2 ischaemia and were treated conservatively. Twenty-
four patients were treated with percutaneous transluminal
angioplasty (PTA), 11 patients received a bypass graft and
two patients underwent an open re-endarterectomy of the
common femoral artery/proximal SFA with proximal patch
plasty.
In univariate analysis, gender was associated with
restenosis. A restenotic lesion was found in 19 of 23 women
(83%) and in 38 of 67 men (57%) within 12 months
(P Z 0.001; Table 1).
Table 1 Clinical characteristicsa.
Characteristics All patients
(n Z 90)
Restenosis
(n Z 57)
No restenosis
(n Z 33)
Hazard ratiob
(95% CI)
P-valueb
Age, mean (range), years 67 (50e84) 67 (50e83) 67 (52e84) 1.18 (0.85e1.65) 0.33
Sex
Male 67 (74) 38 (67) 29 (88) 0.39 (0.22e0.69) 0.001*
Female 23 (26) 19 (33) 4 (12) e
Current smoker 39 (43) 23 (40) 16 (50) 0.76 (0.45e1.30) 0.32
Hypertension 59 (66) 38 (67) 21 (64) 0.99 (0.99e1.01) 0.62
Diabetes Mellitus 27 (30) 17 (30) 10 (30) 1.51 (0.84e2.73) 0.17
Hypercholesterolemia 63 (70) 42 (74) 21 (64) 1.40 (0.77e2.52) 0.27
Body mass index,
mean (range)
26 (17e35) 26 (21e35) 27 (17e32) 0.98 (0.90e1.08) 0.73
Statin use 73 (81) 26 (36) 47 (64) 1.27 (0.43e3.72) 0.67
Acetylsalicylic acid use 75 (83) 26 (35) 49 (65) 1.65 (0.54e5.06) 0.38
Clopidogrel use 24 (27) 8 (33) 16 (67) 1.22 (0.46e3.26) 0.69
Clinical presentationc
Rutherford class III 72 (80) 50 (88) 22 (67) 2.46 (0.34e17.92) 0.38
Rutherford class IV 12 (13) 6 (11) 6 (18) 1.99 (0.24e16.66) 0.53
Rutherford class V 6 (7) 1 (1) 5 (15) Reference
Duration of ischaemic
walking complaints, median
(range), months
56 (4e303) 65 (3e303) 28 (3e248) 1.27 (1.05e1.52) 0.01*
Patent runoff arteries
1 Artery 9 (10) 6 (11) 3 (10) 1.43 (0.59e3.48) 0.44
2 Arteries 32 (36) 23 (40) 9 (29) 1.46 (0.84e2.53) 0.19
3 Arteries 47 (52) 28 (49) 19 (61) Reference
Missing 2 (2) 0 (0) 2 (6)
*P < 0.05.
a Data are presented as No.(%) unless otherwise indicated.
b Cox regression analysis.
c Comparison of Rutherford class III and IV vs. reference.
Figure 2 Restenosis in relation to duration of ischaemic
walking complaints. Patients with longer duration of ischaemic
walking complaints (>median) due to superficial femoral
artery occlusion revealed a significantly (P Z 0.01) higher
incidence of restenosis in the first 12 months postoperatively
than patients with shorter duration of ischaemic walking
complaints (<median).
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ischaemic complaints and RSFAE revealed higher incidence
of restenosis. The median duration of ischaemic walking
complaints before surgery was 65 months (range: 3e303
months) for patients with restenosis and 28 months (range:
3e248 months) in patients without restenosis (Fig. 2). The
risk of restenosis increased with 30% (HR: 1.3 (95% CI: 1.05e
1.52)) per 4 years of ischaemic walking complaints
(P Z 0.012; Table 1).
Histopathological analysis of the excised atherosclerotic
plaques revealed that all femoral arteries were totally
occluded at the time of RSFAE and the atherosclerotic
plaque was dissected between intima and media as
a circular core (Fig. 1).
A small perimeter of the plaque was significantly
associated with restenosis. The median plaque perimeters
were 16.9  4.9 mm in patients with restenosis and
20.2  4.7 mm in those without restenosis (P Z 0.01;
Table 2). Patients with a plaque perimeter smaller than
the median (<17.6 mm) had a significantly higher risk of
restenosis than patients with a larger perimeter (Fig. 3).
The risk of restenosis decreased by 46% per 10-mm
increase of plaque perimeter (HR: 0.54 (95% CI:
0.34e0.88); P Z 0.01).
Consistent with the results of the plaque perimeter, the
median diameters of the SFA lumen, as measured on
Table 2 Per-operative results.
Characteristics (n Z 90) All patients
(n Z 57)
Restenosis
(n Z 33)
No restenosis
(95% CI)
Hazard ratioa P-valuea
Operation time, mean (range), minutes 124 (70e190) 121 (70e187) 129 (70e190) 0.80 (0.62e1.05) 0.10
Blood loss, mean (range), ml 246 (50e1200) 228 (50e500) 280 (50e1200) 0.68 (0.43e1.07) 0.96
Length of dissected intima core,
median (SD), cm
27 (5.6) 25 (6) 28 (4) 0.97 (0.92e1.02) 0.24
Lumen diameter on perioperative
angiography, median (SD), mm
5.7 (1.0) 5.6 (0.9) 6.4 (1.0) 0.46 (0.27e0.78) 0.004*
Perimeter of the plaque,
median (SD), mm
17.6 (5.1) 16.9 (4.9) 20.2 (4.7) 0.54 (0.34e0.88) 0.01*
*P < 0.05.
a Cox regression analysis.
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patients with restenosis (5.6 mm) compared with patients
without restenosis (6.4 mm; Table 2). The risk of restenosis
decreases by 54% per 1.5-mm increase of lumen diameter
as measured on the perioperative angiography (HR: 0.46
(95% CI: 0.27e0.78); P Z 0.004).
Multivariate analysis
As sex, time interval between ischaemic complaints and
RSFAE, plaque perimeter and lumen diameter on peri-
operative angiography were associated with 1-year reste-
nosis, these variables were consequently entered in
multivariate Cox hazard regression analysis. Age and oper-
ation indication (Rutherford category) were always
included in the multivariate analysis models. In multivar-
iate analysis, age (HR: 1.61 (95% CI: 1.03e2.53); PZ 0.04),
duration of ischaemic walking complaints (HR: 1.29 (95% CI:
1.03e1.62); P Z 0.03) and lumen diameter (HR: 0.37 (95%
CI: 0.19e0.72); P < 0.01) were independently associated
with increased risk of restenosis after RSFAE (Table 3).Figure 3 Restenosis in relation to plaque perimeter. Patients
with a smaller perimeter of the plaque (<median) revealed
significantly (P Z 0.01) higher incidence of restenosis in the
first 12 months postoperatively than patients with a larger
perimeter of the plaque (>median).Discussion
Restenosis is a drawback in the first year after RSFAE; thus
far, predictive clinical variables for restenosis are not
available. This study shows that SFA diameter, age and
interval between occurrence of ischaemic walking
complaints and the RSFAE procedure are predictive for
restenosis after RSFAE. These findings may have an effect in
clinical practice. RSFAE should be reconsidered in older
patients, in patients with a long history of ischaemic
complaints and in patients with small SFA diameter. Follow-
up and treatment of restenosis may need to be more
aggressive for these subgroups.
A recently published randomised trial, comparing RSFAE
and supragenicular bypass surgery for long occlusions of the
SFA, concluded that venous bypass is superior to RSFAE.2
However, RSFAE has comparable secondary patency rates
(61%) to prosthetic bypass grafts (63%), with the advantage
of avoiding prosthetic material and shorter hospital stay.2
The difference between the RSFAE patency ratesTable 3 Multivariate cox regression analysisa.
Characteristics Hazard ratio (95% CI) P-value
Age, per 10 years 1.61 (1.03e2.53) 0.04*
Sex
Male e ns
Female e
Clinical presentation
Rutherford class III e ns
Rutherford class IV e
Rutherford class V-VI e
Duration of ischaemic
walking complaints,
per 4 years
1.29 (1.03e1.62) 0.03*
Perimeter of the plaque,
per 10 mm
e ns
Lumen diameter,
per 1.5 mm
0.37 (0.19e0.72) <0.01*
Abbreviations: CI, confidence interval; ns, not significant
(removed from the multivariate model based on likelyhood
ratio).
*P < 0.05.
a Cox regression analysis with backward exclusion of non-
significant variables using likelihood ratio test.
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our study can be explained by the following. Published
studies on RSFAE reported primary patency rates, which is
defined as uninterrupted patency without any procedures
performed on the target lesion. We reported the ‘freedom
of restenosis rate’ and scored all patients with a lumen
reduction of 50% or more as restenosis, although there was
a substantial number of asymptomatic patients who were
treated conservatively (n Z 20). In general, our primary
patency rate is 59% and comparable with the first-year
patency rates of RSFAE (and prosthetic bypass grafts)
described in literature.
The reason to focus on all patients (including asymp-
tomatic patients without re-intervention) with 50%
restenosis is that we wanted to determine both the whole
spectrum of patients with significant lumen reduction after
RSFAE and which factors influence restenosis.
In research considering peripheral artery disease, little
is known about arterial size in relation to restenosis,
although a recent study of bypass surgery showed an
increase of graft restenosis as graft diameter diminished.10
In cardiology, vessel size is well established as an important
determinant of an adverse outcome after re-vascular-
isation.11e13 It is biologically plausible that a reduction in
luminal diameter by a constant amount of neo-intimal
hyperplasia results in a proportionally higher grade of
restenosis in small vessels compared with large ones. Re-
vascularisation results in arterial injury, initiating a prolif-
erative vascular cascade that causes smooth muscle cell
proliferation and migration, resulting in neo-intimal
hyperplasia.13 The amount of neo-intimal hyperplasia is
largely independent of vessel size, and, thus, late luminal
loss, an angiographic measure of neo-intimal hyperplasia, is
similar across a wide range of vessel diameters.14 Accord-
ingly, small vessels are more prone to restenosis than larger
ones because they are less able to accommodate neo-
intimal tissue without compromising blood flow.13
This study found that gender was not an independent
predictive variable for restenosis, although in univariate
analysis women showed significantly more restenosis than
men. Published reports indicate that gender differences in
the risk of restenosis can be explained by the physical size
of the patient. Although coronary artery diameter is highly
related to body size, women have smaller coronary arteries
than men after accounting for differences in body size.
These findings further support the hypothesis that smaller
coronary arteries explain higher perioperative mortality
with coronary artery bypass grafting and poorer outcomes
with other treatments for coronary disease in women and
smaller people.11,15,16
In univariate analysis, age seemed to have no relation
with restenosis. However, in the multivariate model, age
seemed to be an independent predictor for restenosis. The
current way statistical analysis is performed can make this
happen. Usually, only variables showing a relation in the
univariate analysis (typically P < 0.1) are included in the
multivariate analysis. However, these variables could also
be related with each other (confounding). Therefore,
multivariate analysis will discriminate whether these vari-
ables are dependent or independent of each other. We
stated that we always included age (and gender, and
operation indication) in the multivariate analysis.In univariate analysis, age seemed to be confounded to
the null (i.e., showed no relation). However, age was an
independent variable in the multivariate analysis. This can
only be explained if age has been associated with the other
independent variables or a combination of them. In our
study, the ‘older’ patients cannot be compared with the
‘younger’ patients in relation to the other predictive
variables.
We can only speculate about the predictive value of the
duration of ischaemic walking complaints due to SFA
occlusion for restenosis. In most cases, the SFA is occluded
for a long period and will be fibrous. Fibrous plaques have
previously been associated with arterial shrinkage resulting
in smaller vessel size.17,18 Our results suggest that longer
occlusion time and subsequent arterial fibrotic shrinkage
may result in a smaller residual lumen after intervention,
which makes the artery more prone to develop restenosis.
This study may have important implications for the care
and treatment of patients with arterial obstructive disease
in the SFA. Structured exercise and medical treatment
constitute the initial approach to the treatment of inter-
mittent claudication. Failure to respond to this would lead
to limb re-vascularisation.1 Accordingly, almost all patients
undergo operation after a long period of ischaemic
complaints. The median duration of ischaemic walking
complaints in our study was 56 months before surgery. As
explained previously, a likely assumption is that the
occluded fibrous femoral artery will shrink over time.
Subsequently, patients with longer duration of ischaemic
complaints will have smaller arteries with a higher reste-
nosis rate. Therefore, our findings lead to a recommenda-
tion of a more aggressive treatment strategy in a subgroup
of patients. The major challenge, however, is to identify
the subgroup of patients who would benefit from this
aggressive treatment; consequently, a longitudinal study is
required to support this concept.
The known factors influencing outcomes after percuta-
neous intervention include the extent of the disease, use of
a stent, amount of calcification and the runoff below the
knee.5,19e21 The factors influencing the outcome of bypass
surgery focus on the quality of the bypass (graft diameter,
graft length and type of bypass) instead of the extent and
severity of the lesion.5,10 Similar to percutaneous inter-
ventions, bypass surgery for tissue loss has worse outcomes
compared with bypass for claudication.22,23 The reason for
this is not fully understood and is not simply explained by
inflow and outflow levels, because distal origin grafts as
well as pedal bypass grafts have durable results.5,24 In this
study, runoff, TASC classification and operation indication
were not associated with restenosis after RSFAE. It is
notable that recent reports concerning RSFAE also show no
relation between these variables and restenosis.2,25
Our study has several potential limitations. Our data are
prospectively obtained but are retrospectively analysed.
The findings of this study have to be confirmed in a larger
randomised study. Our findings are based on a relatively
small patient group, and confirmation in a larger cohort is
required.
This study is the first of its kind to provide clinical
characteristics that are predictive for RSFAE restenosis in
the first year. Clinicians should reconsider RSFAE in older
patients, patients with a longer history of ischaemic
Predictive Risk Factors for Restenosis 603complaints and in patients with small SFA diameter. Follow-
up and treatment of restenosis may need to be more
aggressive for these subgroups.
Conclusion
This study provides evidence that age, vessel size and
duration of ischaemic walking complaints before RSFAE are
predictive values for restenosis after RSFAE.
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